Published in Clin Cancer Res on May 15, 2006
VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer (2008) 2.09
Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol (2009) 1.80
Vascular disrupting agents in clinical development. Br J Cancer (2007) 1.60
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol (2008) 1.13
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res (2009) 1.10
Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer. Cancer Res (2010) 1.05
Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer (2009) 1.04
Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression. Exp Cell Res (2008) 1.03
Molecular targeted therapies for breast cancer treatment. Breast Cancer Res (2008) 1.03
Bevacizumab and breast cancer: what does the future hold? Future Oncol (2012) 0.92
Antiangiogenic therapy for breast cancer. Breast Cancer Res (2010) 0.90
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. Invest New Drugs (2010) 0.90
TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg Today (2009) 0.89
The emerging importance of α-L-fucose in human breast cancer: a review. Am J Transl Res (2011) 0.89
FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin Cancer Res (2011) 0.88
Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist (2011) 0.87
Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer (2010) 0.86
Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res (2015) 0.84
Bevacizumab. Oncologist (2010) 0.83
Recent concepts of antiangiogenic therapy. Surg Today (2010) 0.83
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest New Drugs (2011) 0.82
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Invest New Drugs (2014) 0.81
Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. Prostate Cancer (2011) 0.81
Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med (2009) 0.81
Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Rev Anticancer Ther (2009) 0.80
Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Retrospective Study of 164 Cases. Medicine (Baltimore) (2015) 0.80
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol (2008) 0.79
Weekly docetaxel in the treatment of metastatic breast cancer. Ther Clin Risk Manag (2008) 0.78
Targeted Therapy: Can It Substitute for Chemotherapy? Breast Care (Basel) (2008) 0.78
First line targeted therapies in breast cancer: focus on bevacizumab. Biologics (2007) 0.76
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat (2012) 0.76
Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro. Breast Cancer (Auckl) (2009) 0.75
Targeted multidrug delivery system to overcome chemoresistance in breast cancer. Int J Nanomedicine (2017) 0.75
Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed? Ther Adv Med Oncol (2010) 0.75
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem (2008) 4.56
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol (2007) 4.45
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Clinical applications of metabolomics in oncology: a review. Clin Cancer Res (2009) 2.91
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res (2004) 2.79
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol (2008) 2.57
Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol (2004) 2.55
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol (2006) 2.51
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol (2009) 2.36
Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov (2006) 2.23
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol (2004) 2.16
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol (2004) 2.13
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol (2013) 1.99
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res (2010) 1.96
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res (2010) 1.96
A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res (2007) 1.89
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83
Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. Clin Cancer Res (2010) 1.76
Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol (2009) 1.74
p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst (2006) 1.74
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood (2008) 1.71
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res (2011) 1.66
Breast cancer version 3.2014. J Natl Compr Canc Netw (2014) 1.63
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov (2010) 1.59
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol (2007) 1.59
Breast Cancer Version 2.2015. J Natl Compr Canc Netw (2015) 1.59
Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab (2005) 1.56
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res (2010) 1.56
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res (2004) 1.55
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther (2009) 1.54
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol (2007) 1.49
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res (2011) 1.48
Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer. Breast Cancer Res Treat (2005) 1.45
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol (2011) 1.45
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst (2010) 1.44
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2012) 1.43
Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One (2013) 1.43
Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst (2004) 1.42
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.40
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol (2006) 1.37
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol (2012) 1.37
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res (2008) 1.36
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
Psychological responses to cancer recurrence. Cancer (2005) 1.34
MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest (2013) 1.34
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest (2004) 1.33
Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res (2009) 1.33
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol (2009) 1.30
NMR-based metabolomics: translational application and treatment of cancer. Curr Opin Mol Ther (2007) 1.30
AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist (2013) 1.29
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis (2013) 1.28
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget (2014) 1.28
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem (2012) 1.27
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat Chem Biol (2012) 1.26
Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int J Clin Exp Pathol (2010) 1.24
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol (2008) 1.23
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol (2010) 1.23
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat (2012) 1.23
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res (2014) 1.23
Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci U S A (2014) 1.22
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat (2008) 1.21
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther (2012) 1.20
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther (2010) 1.19
A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res (2009) 1.19
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res (2006) 1.19
Cancer care and cancer survivorship care in the United States: will we be able to care for these patients in the future? J Oncol Pract (2009) 1.18
Identification of Piwil2-like (PL2L) proteins that promote tumorigenesis. PLoS One (2010) 1.17
Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol (2008) 1.15
Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis (2008) 1.15
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res (2010) 1.15
Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther (2008) 1.15
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol (2014) 1.14